InvestSMART

Syntara Limited (ASX: SNT) - Share Price

- Current share price for SNT : $0.020

Syntara Limited (SNT) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a clinical stage drug development company targeting extracellular matrix dysfunction with its expertise in amine oxidase chemistry and other technologies to develop medicines for blood cancers and conditions linked to inflammation and fibrosis.

SNT General Information +

ASX Code SNT
Website N/A
Industry/Sector Pharmaceuticals
Market Cap ($M) 38
SNT Share Price $0.020
Day High $0.020
Day Low $0.020
Last Close $0.020
SNT Share Price Movement - ( No change )
Prices as at 16:40, 20 Oct 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Syntara Limited (SNT) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Syntara Limited (SNT) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Syntara Limited (SNT) price-sensitive announcements

SNT - Further significant results from SNT-4728 iRBD Phase 2 trial
Syntara Limited (ASX: SNT) announced additional results from its randomised, double-blind,
Syntara Limited (SNT)
7 Oct 2026 | 9:32 AM
SNT - Syntara expands SNT-9465 skin scarring study
Syntara Limited (ASX: SNT) announced that it is expanding the Phase 1b study of its second
Syntara Limited (SNT)
1 Oct 2026 | 9:49 AM
SNT - Appendix 4E and Annual Report
Syntara Limited’s Appendix 4E and Annual Report for the Australian financial year ended 30
Syntara Limited (SNT)
27 Aug 2026 | 2:49 PM
SNT - Quarterly Activities/Appendix 4C Cash Flow Report
Syntara Limited's quarterly report for the period ended 30 June 2026 highlights significan
Syntara Limited (SNT)
27 Jul 2026 | 9:18 AM

Syntara Limited (SNT) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
Syntara Limited (SNT)
ORDINARY FULLY PAID
 Health Care $38 Notice of Annual General Meeting/Proxy Form 20 Oct 2026 11:47AM $0.020 $0.020 fallen by 0%
Syntara Limited (SNT)
ORDINARY FULLY PAID
 Health Care $38 Investor Presentation Canaccord Drug & Device Conference 13 Oct 2026 8:43AM $0.025 $0.020 fallen by 22%
Syntara Limited (SNT)
ORDINARY FULLY PAID
 Health Care $38 Further significant results from SNT-4728 iRBD Phase 2 trial 7 Oct 2026 9:32AM $0.020 $0.020 fallen by 2.50%
Syntara Limited (SNT)
ORDINARY FULLY PAID
 Health Care $38 Notification regarding unquoted securities - SNT 5 Oct 2026 2:24PM $0.021 $0.020 fallen by 7.14%
Syntara Limited (SNT)
ORDINARY FULLY PAID
 Health Care $38 Notification regarding unquoted securities - SNT 5 Oct 2026 2:21PM $0.021 $0.020 fallen by 7.14%
Syntara Limited (SNT)
ORDINARY FULLY PAID
 Health Care $38 Syntara expands SNT-9465 skin scarring study 1 Oct 2026 9:49AM $0.022 $0.020 fallen by 11.36%

SNT Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2026A -$9.61 -$0.60 -30.10% 0.00 0.00 0.00% 0.0%
2025A -$12.26 -$0.80 -42.00% 0.00 0.00 0.00% 0.0%
2024A -$13.67 -$1.40 -17.30% 0.00 0.00 0.00% 0.0%

SNT Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2024 A 2025 A 2026 A 2024 A 2025 A 2026 A 2024 A 2025 A 2026 A
Clarity Pharmaceuticals Ltd (CU6) $668M 0.4454 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Neuren Pharmaceuticals Limited (NEU) $2,497M -0.7857 0.2462 0.9655 84.6584 67.9310 34.5614 0.00% 1.68% 1.98%
Syntara Limited (SNT) $39M -0.3012 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%

SNT Directors

Name Position Start Date
Mr Gary Phillips Chief Executive Officer, Managing Director 12 Mar 2013
Dr Simon Green Non-Executive Director 16 Dec 2022
Mr Waradana Malitha Hashan De Silva Non-Executive Director 16 Jan 2023
Dr Kathleen Mary Metters Non-Executive Director, Non-Executive Chairman 7 Jun 2017

Syntara Limited (SNT) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
20 Feb 2025 DE SILVA, Waradana Issued Indirect Shares 9,753,442 $0.060 $585,206.520
23 Sep 2024 DE SILVA, Waradana Issued Indirect Shares 53,571,429 $0.028 $1,500,000.010
6 Feb 2024 GREEN, Simon Issued Indirect Shares 909,091 $0.022 $20,000.002

See all changes in directors' interest & trades for Syntara Limited (SNT) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

SNT Management

Name Position
Tim Luscombe Company Secretary
Kristen Morgan Other Corporate Officer
Wolfgang Jarolimek Other Corporate Officer
Jana Baskar Other Executive Officer

SNT Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Syntara Limited (SNT). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
349,850,592 (17.83%) D and A Income Limited
219,518,425 (11.19%) Platinum Asset Management Limited

SNT Calendar of Events

Date Event
26 August 2027 Report (Annual)
26 August 2027 Report (Prelim)
25 February 2027 Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.